Local people are to play a major role in deciding how the new, more autonomous foundation hospitals are to be …
The innovative science behind two breakthrough cancer drugs, Novartis’ leukaemia treatment Glivec and Roche’s breast cancer drug Herceptin, has been …
Novartis has questioned the evidence behind a UK licence extension to AstraZeneca breast cancer drug Arimidex.The Medicines Control Agency licence …
Richard Jay Kogan has stepped down as Chairman of Schering-Plough and will relinquish his post as Chief Executive and President …
Merck Sharpe & Dohme's Cozaar has gained a new UK licence for renal protection in patients with type II diabetes …
Eli Lilly is to embark on an ambitious product launch schedule over the next two years to overcome the patent …
The Chief Executive of Bayer has conceded the company cannot continue alone, and has now declared the company open to …
Alzheimer's patients in a quarter of all health authorities are still not receiving the latest medicines despite NICE guidance being …
New networks of excellence in pharmaceutical research must be established if Europe is to catch up with world leading US …
AstraZeneca has been boosted by the first regulatory approval in the Netherlands of Crestor, its 'superstatin' cholesterol treatment.The drug is …
A ban on advertising some OTC medicines could be lifted as part of the Government drive to create a patient-centred …
Patients will be able to report adverse reactions to medicines direct to the NHS from next year, the Government has …
AstraZeneca has launched a new fast acting nasal spray version of its migraine treatment Zomig.The product is intended to bypass …
The growing influence of patient advocacy groups (PAGs) such as the Patients Association is evidence of patient power flexing its …